GlassScriptPhysician profile
Forrest Kenton Busch
NPI 1063425791
$6,322.18
in general payments reported to CMS, 2019-2025
19 companies · $800 in 2025
The $800 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $878 · 2021: $1,262 · 2022: $926 · 2023: $756 · 2024: $951 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,404 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,404.47 |
| Education | $102.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,281.90 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $1,068.56 | 2019-2025 | |
| Janssen Biotech, INC. | $817.23 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Amgen INC. | $482.24 | 2019-2024 | Otezla |
| Pfizer INC. | $281.83 | 2019-2025 | |
| Leo Pharma INC. | $244.41 | 2021-2025 | Adbry, Spevigo |
| Celgene Corporation | $241.98 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $230.10 | 2021-2024 | Dupixent |
| Sun Pharmaceutical Industries INC. | $201.35 | 2019-2022 | |
| Lilly USA, LLC | $121.90 | 2020-2024 | Taltz, Ebglyss |
| Genzyme Corporation | $110.53 | 2019-2021 | |
| Galderma Laboratories, L.P. | $66.77 | 2025 | Nemluvio |
| Mayne Pharma Commercial LLC | $38.29 | 2020-2023 | |
| E.R. Squibb & Sons, L.L.C. | $37.93 | 2023-2024 | Sotyktu |
| Journey Medical Corporation | $32.12 | 2022-2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $30.01 | 2019-2021 | |
| Dermavant Sciences, INC. | $15.09 | 2023 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.43 | 2023 | Spevigo |
| Organon LLC | $6.51 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Forrest Busch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.